O TYM ODCINKU
In this episode of tHEORetically Speaking, join ICON experts Mark McCoy, Dr. Earlene Biggs, Bruce Capobianco, Dr. Tanja Obradovic, Ki Park, and Nancy Risebroughas they answer questions on the Centers for Medicare and Medicaid Services’ negotiations on the fair market prices for Medicare Part D products.
For more information, to watch the webinar, or access other resources, click here.
Język angielski
Stany Zjednoczone
W TYM ODCINKU
TRANSKRYPCJA 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
WYSZUKAJ MINIONE ODCINKI
Wyszukaj minione odcinki tHEORetically Speaking.
INNE ODCINKI W TYM PODCASCIE
This week’s tHEORetically Speaking News Roundup covers Moderna’s progress toward European approval of its combination COVID-19 and flu mRNA vaccine, Novo Nordisk’s $501 million investment to expand Wegovy pill production in Ireland, and Moderna’s $2.25 billion settlement resolving a major mRNA pate…
This week’s tHEORetically Speaking News Roundup covers Takeda’s $1.7B AI-powered drug discovery partnership with Iambic, Moderna’s FDA setback for its mRNA flu vaccine, and AstraZeneca’s decision to keep UK investments on hold despite new pricing reforms. We also explore the launch of a European Li…
This episode features Radek Wasiak, an expert in real world data generation, and real-world evidence. He has provided research services to the life sciences for more than two decades and is currently the director of Adigens Health.
This chat wasn't just a technical deep dive; it was a journey …
In this episode, we explore why the traditional 'clinical-first, value-later' model is becoming a strategic liability and why integrating HEOR into CRO operations is the new industry standard. Join us as Aaron Berger and Dr. Mir Sohail Fazeli break down how to eliminate vendor silos to bu…
This week’s tHEORetically Speaking News Roundup covers new real-world data showing Sanofi’s Beyfortus delivering multi-season protection against RSV hospitalizations, Compass Pathways’ positive Phase 3 results for its psilocybin therapy in treatment-resistant depression, and the FDA’s move toward a…
Zastrzeżenie: Podcast i grafika osadzone na tej stronie pochodzą z HealthEconomics.com, który jest własnością jego właściciela i nie jest powiązany ani wspierany przez Listen Notes, Inc.
EDYTUJ
Dziękujemy za pomoc w aktualizowaniu podcastowej bazy danych.
